X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17828) 17828
Newspaper Article (7216) 7216
Newsletter (1478) 1478
Magazine Article (250) 250
Web Resource (133) 133
Trade Publication Article (114) 114
Book Chapter (82) 82
Government Document (53) 53
Transcript (39) 39
Book / eBook (19) 19
Reference (19) 19
Dissertation (15) 15
Conference Proceeding (9) 9
Book Review (7) 7
Streaming Video (5) 5
Publication (4) 4
Report (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cystic fibrosis (18960) 18960
humans (12898) 12898
male (5065) 5065
female (5022) 5022
cystic-fibrosis (4519) 4519
respiratory system (3800) 3800
cystic fibrosis - drug therapy (3721) 3721
adult (3649) 3649
child (3467) 3467
adolescent (3144) 3144
cystic fibrosis - complications (2857) 2857
animals (2734) 2734
antibiotics (2722) 2722
research (2702) 2702
mutation (2680) 2680
drug therapy (2505) 2505
pharmaceutical industry (2372) 2372
pediatrics (2354) 2354
clinical trials (2251) 2251
infections (2034) 2034
pharmacology & pharmacy (1967) 1967
medical research (1959) 1959
disease (1923) 1923
anti-bacterial agents - therapeutic use (1879) 1879
health aspects (1829) 1829
children (1782) 1782
patients (1778) 1778
care and treatment (1749) 1749
microbiology (1718) 1718
pseudomonas aeruginosa (1682) 1682
child, preschool (1619) 1619
lung diseases (1615) 1615
proteins (1513) 1513
inflammation (1433) 1433
pseudomonas infections - drug therapy (1412) 1412
treatment outcome (1408) 1408
middle aged (1376) 1376
cystic fibrosis - physiopathology (1373) 1373
cystic fibrosis - microbiology (1369) 1369
pseudomonas-aeruginosa (1348) 1348
infectious diseases (1304) 1304
lungs (1291) 1291
infection (1232) 1232
analysis (1227) 1227
studies (1216) 1216
anti-bacterial agents - administration & dosage (1211) 1211
asthma (1199) 1199
medicine, experimental (1192) 1192
cystic fibrosis transmembrane conductance regulator - genetics (1182) 1182
administration, inhalation (1168) 1168
drugs (1137) 1137
bacteria (1128) 1128
cystic fibrosis - metabolism (1117) 1117
mice (1115) 1115
cystic fibrosis - genetics (1114) 1114
medicine (1112) 1112
infant (1104) 1104
therapy (1102) 1102
fibrosis (1085) 1085
young adult (1082) 1082
cystic fibrosis - therapy (1060) 1060
genetic aspects (1022) 1022
pseudomonas aeruginosa - drug effects (984) 984
anti-bacterial agents - pharmacology (979) 979
chronic obstructive pulmonary disease (956) 956
immunology (933) 933
medicine, general & internal (908) 908
pulmonary/respiratory (881) 881
biochemistry & molecular biology (880) 880
research article (874) 874
transmembrane conductance regulator (874) 874
gene therapy (864) 864
risk factors (851) 851
fda approval (833) 833
bacterial infections (816) 816
mortality (784) 784
microbial sensitivity tests (781) 781
drug dosages (767) 767
medicine, research & experimental (753) 753
in-vitro (746) 746
diagnosis (743) 743
cftr (738) 738
cell biology (733) 733
research & development--r&d (733) 733
aged (726) 726
enzymes (725) 725
multidisciplinary sciences (724) 724
cystic fibrosis transmembrane conductance regulator - metabolism (720) 720
drug resistance (720) 720
expression (708) 708
retrospective studies (704) 704
tobramycin (672) 672
pseudomonas infections - microbiology (660) 660
earnings per share (655) 655
biofilms (644) 644
biotechnology industry (635) 635
abridged index medicus (633) 633
chronic disease (632) 632
critical care medicine (631) 631
cystic-fibrosis patients (631) 631
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (7) 7
Online Resources - Online (3) 3
New College (Ivey) - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (26717) 26717
French (240) 240
German (160) 160
Spanish (76) 76
Italian (56) 56
Russian (48) 48
Portuguese (40) 40
Dutch (20) 20
Japanese (19) 19
Polish (17) 17
Turkish (9) 9
Danish (8) 8
Czech (7) 7
Chinese (4) 4
Hebrew (4) 4
Swedish (3) 3
Hungarian (2) 2
Norwegian (2) 2
Romanian (2) 2
Slovenian (2) 2
Arabic (1) 1
Bosnian (1) 1
Croatian (1) 1
Lithuanian (1) 1
Slovak (1) 1
Ukrainian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature medicine, ISSN 1546-170X, 2017, Volume 23, Issue 5, pp. 590 - 600
Journal Article
Nature medicine, ISSN 1546-170X, 2018, Volume 24, Issue 11, pp. 1732 - 1742
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 21, pp. 2013 - 2023
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 3, pp. 220 - 231
Journal Article
American journal of respiratory and critical care medicine, ISSN 1535-4970, 2014, Volume 190, Issue 2, pp. 175 - 184
Rationale: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6 and older with the G551D mutation... 
Cystic fibrosis | Pseudomonas aeruginosa | Ivacaftor | CFTR modulator | LUNG-FUNCTION | ivacaftor | MUCIN SECRETION | ADRENERGIC SWEAT SECRETION | MUCOCILIARY CLEARANCE | INTESTINAL PH | CHILDREN | RESPIRATORY SYSTEM | cystic fibrosis | PSEUDOMONAS-AERUGINOSA | INFLAMMATION | DISEASE | QUESTIONNAIRE | CRITICAL CARE MEDICINE | Sputum - microbiology | Lung - microbiology | Pseudomonas aeruginosa - isolation & purification | Follow-Up Studies | Forced Expiratory Volume - drug effects | Sweat - drug effects | Humans | Microbiota - drug effects | Respiratory System Agents - therapeutic use | Hospitalization - statistics & numerical data | Male | Aminophenols - therapeutic use | Quinolones - pharmacology | Aminophenols - pharmacology | Mucociliary Clearance - drug effects | Pseudomonas Infections - prevention & control | Young Adult | Hydrogen-Ion Concentration - drug effects | Quinolones - therapeutic use | Adult | Female | Lung - metabolism | Child | Biomarkers - metabolism | Respiratory System Agents - pharmacology | Cystic Fibrosis - metabolism | Cystic Fibrosis - microbiology | Pseudomonas Infections - complications | Pseudomonas Infections - diagnosis | Treatment Outcome | Lung - physiopathology | Genetic Markers | Sputum - metabolism | Cystic Fibrosis - genetics | Intestine, Small - drug effects | Lung - drug effects | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Intestine, Small - metabolism | Mutation | Cystic Fibrosis - drug therapy | Sweat - metabolism | Original
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2019, Volume 2019, Issue 1, p. CD009841
Background Cystic fibrosis (CF) is the commonest inherited life‐shortening illness in white populations, caused by a mutation in the gene that codes for the cystic fibrosis transmembrane regulator protein (CFTR... 
GENE THERAPY | Genetic disorders | Lungs & airways | Age Factors | Cystic Fibrosis | CORRECTION OF THE MOLECULAR DEFECT | Mucociliary Clearance | TREATMENT | CORRECTING THE BASIC DEFECT IN CF | Cystic fibrosis: other treatments | Molecular Targeted Therapy | Aminophenols | Cystic Fibrosis Transmembrane Conductance Regulator | Quinolones | Randomized Controlled Trials as Topic | Forced Expiratory Volume | Clinical Trials, Phase III as Topic | Chloride Channel Agonists | Child health | Quality of Life | Fibrosis: cystic fibrosis | Mutation | Medicine General & Introductory Medical Sciences | Clinical Trials, Phase II as Topic | SWEAT CHLORIDE | EFFICACY | SAFETY | Humans | G551D MUTATION | MEDICINE, GENERAL & INTERNAL | Aminophenols [therapeutic use] | Molecular Targeted Therapy [methods] | IN-VITRO | DIFFERENCE | Forced Expiratory Volume [drug effects] | Adult | Child | Cystic Fibrosis Transmembrane Conductance Regulator [drug effects; genetics] | PHASE-II | IVACAFTOR RESPONSE | CFTR POTENTIATOR | Cystic Fibrosis [drug therapy; genetics] | Quinolones [therapeutic use] | DOUBLE-BLIND | Forced Expiratory Volume - drug effects | Chloride Channel Agonists - therapeutic use | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Mutation - genetics | Aminophenols - adverse effects | Cystic Fibrosis Transmembrane Conductance Regulator - drug effects | Quinolones - adverse effects | Cystic Fibrosis - genetics | Quinolones - therapeutic use | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Cystic Fibrosis - drug therapy | Molecular Targeted Therapy - methods
Journal Article